Q-omics provides the consensus-scored H3P33 profile across patient tissues and cancer cell-line models. H3P33 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, H3P33 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, H3P33 RNA expression shows 6,304 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where H3P33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H3P33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H3P33 survival associations across molecular data types. H3P33 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H3P33 RNA expression–survival associations across cancer types. High H3P33 expression shows unfavorable associations in KIRC, STAD, COAD, LUAD, UVM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .018). Together, the overview and detailed table identify KIRC as the clearest survival context for H3P33 RNA expression.
This table summarizes H3P33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for H3P33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H3P33 shows lower tumor expression in BRCA and KIRP and higher tumor expression in LIHC. The BRCA box plot shows higher H3P33 RNA expression in normal versus tumor tissue (log2 FC = −0.091, t-test p = .002).
This table shows molecular features associated with H3P33 in patient tissues and cancer cell lines. In patient samples, H3P33 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
